

Real World Evidence Solutions Market is Expected to Reach USD 78.83 billion 2030

Real World Evidence (RWE) Solutions
Market Shows Exponential Growth,
Driven by Rising Prevalence of Chronic
Diseases and Pharmaceutical
Collaborations

AUSTIN, TEXAS, UNITED STATES, January 17, 2024 /EINPresswire.com/ -- The SNS Insider report indicated that the size for Real World Evidence (RWE) Solutions Market was estimated to be USD 43.22 billion in 2022, with a projected compound annual growth



rate (CAGR) of 7.8% from 2023 to 2030, anticipating a total value of USD 78.83 billion by the year 2030.

As per SNS Insider's research collaborations between pharmaceutical companies and technology providers contribute to the real-world evidence/RWE solutions market's expansion.

Real World Evidence Solutions Market Report Scope

Real-world evidence (RWE) solutions encompass a set of methodologies and technologies aimed at collecting and analyzing data from real-world patient experiences. These solutions have become integral in the healthcare landscape, providing valuable insights beyond traditional clinical trials. Key elements of RWE solutions include electronic health records, claims data, patient registries, and observational studies.

Real World Evidence Solutions Market Analysis

The real world evidence/RWE solutions marketis poised for substantial growth, driven by several key factors. The integration of RWE in healthcare decision-making processes, the rise in chronic diseases, and the emphasis on patient-centric approaches are pivotal drivers. Additionally, the expansion of healthcare data analytics capabilities and advancements in technology contribute to the market's upward trajectory. The growing collaboration between pharmaceutical

companies and technology providers further propels the adoption of RWE solutions. RWE supports a patient-centric healthcare model, influencing treatment decisions and personalized medicine. The increasing prevalence of chronic diseases fuels the demand for RWE solutions to enhance treatment effectiveness.

Impact of Recession

The ongoing recession has both positive and negative implications for the real world evidence/RWE solutions market. On one hand, cost-conscious healthcare providers may seek more cost-effective and efficient solutions, boosting the adoption of RWE. Conversely, budget constraints and reduced healthcare spending may lead to delays in technology investments and RWE implementation, impacting market growth. Recession-induced cost consciousness may drive healthcare providers to seek cost-effective RWE solutions. Budget constraints during a recession may result in delays in technology investments, affecting the pace of RWE adoption.

Impact of Russia-Ukraine WarThe Russia-Ukraine war introduces geopolitical uncertainties that may affect the real world evidence/RWE solutions market. Disruptions in the global supply chain, economic instability, and shifts in geopolitical alliances could impact the adoption of RWE solutions. On the positive side, increased focus on healthcare resilience and preparedness may drive investments in innovative healthcare technologies, including RWE solutions. Geopolitical tensions may lead to disruptions in the global supply chain, affecting the availability of RWE technologies. Economic uncertainties resulting from the war may impact healthcare budgets, potentially influencing RWE adoption rates.

By Component Type

- Services
- Pharmacy data
- · Clinical setting data
- · Data Sets
- Claims data
- · Patient powered data

By Therapeutic area Type

- Cardiovascular
- Oncology
- Immunology
- Neurology
- Others

By End Users

- Healthcare Providers
- Pharmaceutical and Medical Devices Companies
- Healthcare Payers

Key Regional Development

In North America, the real world evidence/RWE solutions market is driven by a well-established healthcare infrastructure, favorable regulatory support, and a high prevalence of chronic diseases. The region's advanced technology adoption and collaboration between industry players contribute to sustained market growth. Europe showcases a growing demand for RWE solutions, supported by a robust healthcare system and increasing emphasis on evidence-based medicine. Regulatory frameworks that encourage RWE adoption and the presence of key market players enhance the market's dynamics. The Asia-Pacific region is witnessing rapid growth in RWE solutions adoption due to expanding healthcare infrastructure, rising healthcare expenditures, and the growing awareness of the benefits of real-world evidence in clinical decision-making.

- IBM
- PPD, Inc.
- IQVIA
- Parexel International Corp.
- Syneos Health
- Icon Plc
- Medpace
- PerkinElmer, Inc.
- Oracle
- Cegedim Health Data

Key Takeaway from Real World Evidence/RWE Solutions Market Study

• The cardiovascular segment is poised to dominate the market due to the high prevalence of cardiovascular diseases worldwide. RWE solutions offer valuable insights into the long-term effectiveness and safety of cardiovascular treatments. The integration of real-world evidence in cardiovascular research and treatment decision-making enhances patient outcomes and supports evidence-based practices.

• The pharmacy data segment is expected to dominate the real world evidence/RWE solutions market as it plays a crucial role in understanding medication utilization, adherence, and outcomes. With the increasing emphasis on personalized medicine and the role of medications in healthcare, pharmacy data integrated with RWE solutions becomes a cornerstone for evidence-based decision-making.

Recent Developments Related to Real World Evidence/RWE Solutions Market

- Inspire, a leading in the healthcare industry, has recently unveiled a groundbreaking initiative centered around patient-driven real-world evidence (RWE). This strategic move encompasses a range of innovative data and analytic solutions aimed at revolutionizing the landscape of healthcare research and analysis.
- Flatiron Health has also stepped into the arena of Real-World Evidence with a focus on Oncology. Leveraging its expertise in healthcare technology, Flatiron Health introduces integrated RWE solutions tailored specifically for the intricacies of oncological research and treatment.

https://www.snsinsider.com/checkout/1787

Akash Anand
SNS Insider Pvt. Ltd
+1 415-230-0044
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
Instagram

YouTube

This press release can be viewed online at: https://www.einpresswire.com/article/681884026

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.